Germany's Merck completes sale of consumer business for 3.4 billion euros

30 November 2018
mergers-acquisitions-big

German life sciences group Merck KGaA (MRK: DE) has successfully completed the sale of its Consumer Health business to Procter & Gamble (NYSE: PG), giving the latter vitamin brands such as Seven Seas, Femibion and Neurobion, and greater exposure to Latin American and Asian markets.

The successful completion of the transaction marks a further step in the company’s strategic focus on innovation driven businesses and transformation towards a leading science and technology company. The business transferred to P&G on December 1, 2018. The cash purchase price is approximately 3.4 billion euros ($3.86 billion).

As part of the deal, P&G will buy a majority stake in Merck’s Indian consumer health business, and subsequently make a mandatory tender offer to minority shareholders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical